Loading…
Korean biotech developing an RNAi (siRNA) therapeutics platform, licensing candidates for eye, skin and other diseases to global partners.
Korean biotech developing an RNAi (siRNA) therapeutics platform, licensing candidates for eye, skin and other diseases to global partners.
No product sales; income is licence payments, such as an upfront fee when a partner signs and milestones if its programmes progress, so revenue is irregular and depends on partners. It develops drugs through early stages and typically relies on partners for the later, costlier ones.
Moat: narrow (IP / patents). Proprietary asymmetric siRNA (cp-asiRNA) platform, a differentiated RNAi drug-design approach.
Headquarters: Suwon, South Korea · Founded: 2010 · Employees: 76
Size OliX Pharmaceuticals (226950.KS) is a South Korea Health Care company (Pharmaceuticals: Major) with a market value of $1.26B, the 202nd largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩74,800 on 6 Nov 2026.
Performance Over six months the shares fell 56.6%, against -12.3% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 21 in its peer set.
Growth Revenue grew 80.9% over the last twelve months (peer median +3.0%); the operating margin is -304.7% (peer median 2.8%).
Valuation It trades at 111.4× enterprise value to sales against a peer median of 4.5× (3rd most expensive of 18).
Capital Return on invested capital runs 72.7 points below its cost of capital (6.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩13.6B | ₩14.7B | ₩5.68B | ₩17.1B | ₩9.32B |
| Revenue growth | — | +158% | -67% | +83% | — |
| Gross profit | ₩11.3B | ₩12.2B | ₩3.05B | ₩14.4B | ₩7.35B |
| EBITDA | -₩39.2B | -₩27.5B | -₩28.3B | -₩15.5B | -₩20.4B |
| Net income | -₩14.0B | -₩15.7B | -₩40.7B | -₩19.1B | -₩19.5B |
| Free cash flow | -₩31.5B | -₩17.2B | -₩42.1B | -₩29.9B | -₩32.9B |
| Capital expenditure | ₩2.23B | ₩1.86B | ₩14.1B | ₩8.96B | ₩2.53B |
| Total debt | ₩20.8B | ₩23.3B | ₩39.2B | ₩39.4B | ₩44.0B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| OliX Pharmaceuticals 226950.KS | $1.26B | -57% | +81% | -305% | 111.4× | n/a |
| Alnylam Pharmaceuticals ALNY | $20.9B | -47% | +56% | 20% | 4.0× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 226950.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -39.0% | -5.4% | lowest of 21 |
| 6-month return | -56.6% | -12.3% | 2nd lowest of 21 |
| Distance from 52-week high | -65.5% | -40.5% | 4th lowest of 21 |
| Revenue growth (TTM) | +80.9% | +3.0% | 2nd highest of 17 |
| Operating margin | -304.7% | 2.8% | 4th lowest of 18 |
| EV / Sales | 111.4× | 4.5× | 3rd most expensive of 18 |
| ROIC minus cost of capital | -72.7 pp | -5.0 pp | 3rd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| OliX Pharmaceuticals 226950.KS | South Korea | $1.26B | -57% | +81% | -305% | 111.4× | n/a | n/a |
| MannKind MNKD | United States | $1.25B | +11% | +30% | 3% | 4.0× | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.27B | -29% | +14% | 11% | 3.0× | 11.7% | +18.1% |
| Nektar Therapeutics NKTR | United States | $1.27B | -54% | -27% | -239% | 13.3× | n/a | n/a |
| GH Research GHRS | United States | $1.28B | -13% | n/a | n/a | n/a | n/a | n/a |
| D&D Pharmatech 347850.KS | South Korea | $1.28B | -49% | -71% | -1,368% | 617.6× | n/a | n/a |
| PYC Therapeutics PYC.AX | Australia | $1.28B | +31% | n/a | n/a | n/a | n/a | n/a |
| Avalyn Pharma AVLN | United States | $1.29B | +7% | n/a | n/a | n/a | n/a | n/a |
| Omeros OMER | United States | $1.22B | +14% | n/a | -190% | 36.2× | n/a | n/a |
| Everest Medicines 1952.HK | Hong Kong | $1.22B | -20% | +193% | -5% | 3.5× | n/a | n/a |
| Voronoi 310210.KS | South Korea | $1.31B | -66% | +24% | -1,947% | 417.6× | n/a | n/a |
| Sinopep-Allsino Bio Pharmaceutical 688076.SS | China | $1.31B | -7% | +14% | 19% | 5.0× | 4.0% | +27.9% |
| Amphastar Pharmaceuticals AMPH | United States | $1.21B | +50% | +1% | 16% | 2.2× | 3.3% | +15.5% |
| Changzhou Qianhong Bio-Pharma 002550.SZ | China | $1.21B | -8% | -2% | 15% | 4.5× | 4.5% | -1.2% |
| C.Q. Pharmaceutical 000950.SZ | China | $1.32B | -12% | -3% | 1% | 0.5× | n/a | n/a |
| Tianjin Chase Sun Pharmaceutical 300026.SZ | China | $1.32B | -6% | -29% | 3% | 2.0× | 8.5% | -5.3% |
| Jiuzhitang 000989.SZ | China | $1.19B | -13% | +46% | 19% | 2.6× | -3.7% | -9.0% |
| Hanall Biopharma 009420.KS | South Korea | $1.34B | -25% | +5% | 3% | 11.2× | n/a | n/a |
| Lotus Pharmaceutical 1795.TW | Taiwan | $1.34B | -26% | +49% | 24% | 3.4× | -2.4% | +13.8% |
| InventisBio 688382.SS | China | $1.19B | -41% | -61% | -563% | 94.5× | 10.4% | -60.6% |
| Idorsia IDIA.SW | Switzerland | $1.34B | -5% | -5% | -70% | 10.7× | n/a | n/a |